title: Ophthalmologic findings in hepatitis C patients treated with pegylated interferon α-2b and ribavirin.
abstract: OBJECTIVE
  To identify the effect of pegylated interferon ƒ¿-2b and ribavirin treatment in the ocular fundus examination, visual acuity, and visual field.
  
  
  METHODS
  Prospective observational study was performed at the Hepatology Clinic of Sao Jose Regional Hospital and at the Vitreoretinal Department at the Sadalla Amin Ghanem Eye Hospital in patients with chronic hepatitis C before and during treatment with pegylated interferon ƒ¿-2b together with ribavirin.
  
  
  RESULTS
  Six (37.5%) of 16 patients developed retinopathy during the treatment, two of which (12.5%) presented retinal hemorrhage, and four patients (6 eyes) presented cotton-wool spots (25%) that regressed during the treatment. One patient (6.25%) presented transient decrease in visual acuity during the treatment and recovered spontaneously without specific therapy.
  
  
  CONCLUSIONS
  Recommended treatment methods for hepatitis C may cause transient retinopathy, commonly without any damage to visual function in most patients. Although ocular involvement is rare, follow-up with an ophthalmologist is recommended during the course of the hepatitis C medication.
authors.affiliation: Sadalla Amin Ghanem Eye Hospital.
authors.forename: Fernando José de
authors.initials: FJ
authors.lastname: Novelli
authors.affiliation: Sadalla Amin Ghanem Eye Hospital.
authors.forename: André
authors.initials: A
authors.lastname: Przysiezny
authors.affiliation: Sadalla Amin Ghanem Eye Hospital.
authors.forename: Evandro Luis
authors.initials: EL
authors.lastname: Rosa
authors.affiliation: City Program of Viral Hepatitis Control, Joinville, SC, Brazil.
authors.forename: Raquel Francine Liermann
authors.initials: RF
authors.lastname: Garcia
authors.affiliation: Sadalla Amin Ghanem Eye Hospital.
authors.forename: Mário Junqueira
authors.initials: MJ
authors.lastname: Nóbrega
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000009:adverse effects*; D005260:Female; D005451:Fluorescein Angiography; D005654:Fundus Oculi; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000009:adverse effects*; D011446:Prospective Studies; D011994:Recombinant Proteins / Q000009:adverse effects; D012164:Retinal Diseases / Q000139:chemically induced*; D012254:Ribavirin / Q000009:adverse effects*; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome; D014792:Visual Acuity / Q000187:drug effects; D014794:Visual Fields / Q000187:drug effects; D055815:Young Adult
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C417083:peginterferon alfa-2b